News

Business Wire2d
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
Elderly people with dementia being subjected to violence, abuse and neglect in their own homes
There's a clear downside to the Norwegian policy that encourages allowing elderly people to live at home for as long as ...
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
MPR17h
FDA Approves Oral Ekterly for On-Demand Hereditary Angioedema Treatment
The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Fierce Pharma1d
KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly
After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...
Elderly flower farmer killed in Maili blaze remembered for warm smile, gentle nature
Maria Pasqual was a flower farmer in Maili, loved by those who encountered her. The family who lives next door to her farm ...